Research analysts at B. Riley assumed coverage on shares of Miragen Therapeutics (NASDAQ:MGEN) in a research report issued to clients and investors on Friday, January 5th, MarketBeat.com reports. The firm set a “buy” rating and a $15.50 price target on the medical research company’s stock. B. Riley’s target price suggests a potential upside of 91.12% from the company’s previous close.
Other equities analysts have also issued research reports about the company. Wedbush reiterated a “buy” rating and issued a $19.00 target price on shares of Miragen Therapeutics in a research note on Friday, December 1st. Zacks Investment Research upgraded Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research note on Friday, November 17th. Finally, Chardan Capital restated a “buy” rating and set a $29.00 price target on shares of Miragen Therapeutics in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $16.46.
Shares of Miragen Therapeutics (NASDAQ:MGEN) opened at $8.11 on Friday. Miragen Therapeutics has a fifty-two week low of $6.02 and a fifty-two week high of $18.00. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.04.
In other news, Director Thomas E. Hughes sold 12,000 shares of the business’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $8.00, for a total transaction of $96,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 44.40% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of MGEN. SG Americas Securities LLC purchased a new stake in Miragen Therapeutics in the third quarter valued at approximately $250,000. BSW Wealth Partners purchased a new stake in Miragen Therapeutics in the third quarter valued at approximately $203,000. Russell Investments Group Ltd. purchased a new stake in Miragen Therapeutics in the third quarter valued at approximately $147,000. Finally, Seaward Management Limited Partnership acquired a new position in Miragen Therapeutics in the third quarter valued at approximately $117,000. Hedge funds and other institutional investors own 22.64% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Miragen Therapeutics (MGEN) Coverage Initiated at B. Riley” was published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/miragen-therapeutics-mgen-coverage-initiated-at-b-riley/1820700.html.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.